# Sorafenib, Epirubicin, Ifosfamide, and Radiation Therapy Followed By Surgery in Treating Patients With High-Risk Stage II or Stage III Soft Tissue Sarcoma

> **NCT00822848** · PHASE1 · COMPLETED · sponsor: **OHSU Knight Cancer Institute** · enrollment: 18 (actual)

## Conditions studied

- Sarcoma

## Interventions

- **DRUG:** epirubicin hydrochloride
- **DRUG:** ifosfamide
- **DRUG:** sorafenib tosylate
- **OTHER:** immunoenzyme technique
- **OTHER:** immunohistochemistry staining method
- **OTHER:** laboratory biomarker analysis
- **PROCEDURE:** adjuvant therapy
- **PROCEDURE:** neoadjuvant therapy
- **PROCEDURE:** therapeutic conventional surgery
- **RADIATION:** hypofractionated radiation therapy

## Key facts

- **NCT ID:** NCT00822848
- **Lead sponsor:** OHSU Knight Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-02
- **Primary completion:** 2012-09
- **Final completion:** 2013-04-30
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2018-09-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00822848

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00822848, "Sorafenib, Epirubicin, Ifosfamide, and Radiation Therapy Followed By Surgery in Treating Patients With High-Risk Stage II or Stage III Soft Tissue Sarcoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00822848. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*